The End­points 11: The biotech star­tups mak­ing the biggest bets with the most ex­cit­ing sci­ence in 2023

Every year, with­out fail, the End­points 11 proves to be the most chal­leng­ing project I face — and def­i­nite­ly re­mains the most fun.

In an in­dus­try where am­bi­tion and zeal are trade­marks of the most ex­cit­ing biotechs, how do you nar­row the list down to 11 of the most wor­thy new drug de­vel­op­ers to hit the scene?

With­out doubt the sci­ence re­mains the cru­cial el­e­ment. You have to look for an im­por­tant ad­vance to make your mark in biotech, and that means track­ing down cut­ting-edge labs that have be­come skilled at ex­plor­ing new op­por­tu­ni­ties. Drug de­vel­op­ment is ex­tra­or­di­nar­i­ly ex­pen­sive, and that means the back­ers have to of­fer cred­i­bil­i­ty with a rep for play­ing out the game. You can’t have a syn­di­cate of shaky play­ers when you em­bark on a jour­ney of years. And then there’s the man­age­ment team: the peo­ple bet­ting a big chunk of their lives that they can ac­com­plish some­thing of re­al im­por­tance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER